Get started
ADMA Biologics IncADMA Biologics IncADMA Biologics Inc

ADMA Biologics Inc

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

ADMA chart


Full chart

ADMA upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪5.08 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
26.33
Basic EPS (TTM)
0.84 USD
Net income (FY)
‪197.67 M‬ USD
Revenue (FY)
‪426.45 M‬ USD
Shares float
‪230.23 M‬
Beta (1Y)
1.27

Employees


Employees (FY)
685
Change (1Y)
+61 +9.78%
Revenue / Employee (1Y)
‪622.56 K‬ USD
Net income / Employee (1Y)
‪288.57 K‬ USD

About ADMA Biologics Inc


Sector
Health Technology
Industry
Biotechnology
CEO
Adam S. Grossman
Website
admabiologics.com
Headquarters
Ramsey
Founded
2004
FIGI
BBG002NCK5M5
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ADMA news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as ADMA.

Frequently Asked Questions


The current price of ADMA is 19.64 USD — it has decreased by −8.49% in the past 24 hours. Watch ADMA Biologics Inc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange ADMA Biologics Inc stocks are traded under the ticker ADMA.
ADMA stock has fallen by −3.85% compared to the previous week, the month change is a −0.71% fall, over the last year ADMA Biologics Inc has showed a 216.78% increase.
We've gathered analysts' opinions on ADMA Biologics Inc future price: according to them, ADMA price has a max estimate of 32.00 USD and a min estimate of 25.00 USD. Watch ADMA chart and read a more detailed ADMA Biologics Inc stock forecast: see what analysts think of ADMA Biologics Inc and suggest that you do with its stocks.
ADMA reached its all-time high on Nov 11, 2024 with the price of 23.64 USD, and its all-time low was 1.01 USD and was reached on Oct 21, 2021. View more price dynamics on ADMA chart.
See other stocks reaching their highest and lowest prices.
ADMA stock is 14.84% volatile and has beta coefficient of 1.27. Track ADMA Biologics Inc stock price on the chart and check out the list of the most volatile stocks — is ADMA Biologics Inc there?
Today ADMA Biologics Inc has the market capitalization of ‪5.08 B‬, it has increased by 14.23% over the last week.
Yes, you can track ADMA Biologics Inc financials in yearly and quarterly reports right on TradingView.
ADMA Biologics Inc is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
ADMA earnings for the last quarter are 0.14 USD per share, whereas the estimation was 0.15 USD resulting in a −6.03% surprise. The estimated earnings for the next quarter are 0.16 USD per share. See more details about ADMA Biologics Inc earnings.
ADMA Biologics Inc revenue for the last quarter amounts to ‪117.55 M‬ USD, despite the estimated figure of ‪112.77 M‬ USD. In the next quarter, revenue is expected to reach ‪116.40 M‬ USD.
ADMA net income for the last quarter is ‪111.90 M‬ USD, while the quarter before that showed ‪35.91 M‬ USD of net income which accounts for 211.61% change. Track more ADMA Biologics Inc financial stats to get the full picture.
No, ADMA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 21, 2025, the company has 685 employees. See our rating of the largest employees — is ADMA Biologics Inc on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ADMA Biologics Inc EBITDA is ‪147.03 M‬ USD, and current EBITDA margin is 34.48%. See more stats in ADMA Biologics Inc financial statements.
Like other stocks, ADMA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ADMA Biologics Inc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ADMA Biologics Inc technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ADMA Biologics Inc stock shows the buy signal. See more of ADMA Biologics Inc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.